Comparative Pharmacology
Head-to-head clinical analysis: MAXAIR versus THEOCLEAR L A 130.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAXAIR versus THEOCLEAR L A 130.
MAXAIR vs THEOCLEAR L.A.-130
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle via increased intracellular cAMP.
Theophylline is a methylxanthine that inhibits phosphodiesterase, increasing intracellular cAMP, and blocks adenosine receptors, leading to bronchodilation and anti-inflammatory effects.
2 inhalations (340 mcg) via oral inhalation every 4-6 hours as needed for bronchospasm; not to exceed 12 inhalations per day.
130 mg orally every 12 hours; extended-release tablet.
None Documented
None Documented
3.5–4.0 hours; clinically, this supports dosing every 4–6 hours as needed.
Terminal elimination half-life is 3-8 hours in healthy adults (mean 5-6 hours). It is prolonged in patients with hepatic cirrhosis, heart failure, or COPD (up to 30 hours) and in neonates (20-30 hours). Smoking induces metabolism, reducing half-life to 1-4 hours.
Renal excretion of unchanged drug accounts for approximately 90% of elimination; fecal excretion is minimal (<5%).
Approximately 90% of theophylline is eliminated hepatically via CYP1A2 and CYP3A4 metabolism; renal excretion of unchanged drug accounts for about 10% in adults, but may increase to 50% in neonates. Biliary/fecal elimination is negligible.
Category C
Category C
Bronchodilator
Bronchodilator